The American Hospital Association argues new policies from Eli Lilly and Novo Nordisk requiring providers to submit more ...

The hospital lobby is asking federal officials to head off expanded data collection policies some drugmakers are implementing for providers participating in the 340B drug discount program.

AHA urges HHS to block Novo Nordisk's 340B data demand, citing legal and cost concerns for safety-net hospitals and covered entities.

A new report paints a stark picture of how a subset of large healthcare providers are drawing the lion’s share of 340B savings within a single state.  | A Minnesota analysis of providers' reported ...

AbbVie loses bid to block Tennessee 340B law as federal court upholds state statute limiting drugmaker restrictions on contract pharmacies.

The 340B Drug Pricing Program (the Program) has long been a cornerstone for healthcare providers seeking to deliver affordable care to underserved communities. However, as the regulatory and ...

The drug discount program is under scrutiny on a variety of fronts ...

The 340B drug discount program has followed a familiar health policy trajectory. An intervention that was supposed to ease cost pressures, it instead is producing cascading unintended consequences ...

The 340B drug discount program incentivizes hospitals to purchase outpatient clinics and prescribe more and higher-cost drugs — behaviors that tend to increase costs for the federal government and ...

The rapid expansion of the federal 340B drug pricing program is significantly affecting Medicaid budgets, particularly in states where managed care plans oversee prescription drug benefits. New ...

There are times when more isn’t better. It’s just more. This is one of those times. Democratic legislators are pushing Senate ...

The 340B Drug Pricing Program entitles participating hospitals and clinics (called covered entities) to purchase outpatient drugs at a substantial discount from manufacturers. Covered entities either ...